Multiple Myeloma in 2026: MRD-Guided Approval, Quadruplet Frontline Therapy, and Immunotherapy Moving Earlier

Multiple myeloma (搜索)搜索该疾病 treatment has entered a period of rapid transformation, with minimal residual disease (MRD) now informing regulatory decisions, quadruplet regimens anchoring frontline care, and immunotherapy moving into earlier lines of therapy. In August 2026, the FDA granted accelerated approval to iberdomide查看药品详情 plus daratumumab查看药品详情 and dexamethasone for patients who have received at least one prior line containing a proteasome inhibitor and an immunomodulatory agent, a decision supported by MRD-negative complete response entering regulatory decision-making for the first time.

Multiple myeloma (搜索)搜索该疾病 accounts for approximately 10% of hematologic malignancies and primarily affects older adults, with a median age at diagnosis of 65 years. More than 36,000 new cases are diagnosed annually in the US, with higher incidence in men. Almost all multiple myeloma develops from monoclonal gammopathy of undetermined significance (搜索)搜索该疾病 (MGUS), an asymptomatic precursor state found in roughly 5% of people older than 50 years, which progresses to multiple myeloma or a related malignancy at an average rate of about 1% per year.

Diagnosing Myeloma Before Organ Damage Occurs

The diagnosis of multiple myeloma (搜索)搜索该疾病 requires at least 10% clonal plasma cells in the bone marrow, or a biopsy-proven plasmacytoma, together with at least one myeloma-defining event. The classic CRAB manifestations—hypercalcemia, renal impairment, anemia, and osteolytic bone disease—remain central, but current International Myeloma Working Group (IMWG) criteria also recognize three biomarkers capable of defining active disease before CRAB-related damage occurs: clonal bone marrow plasma cells of at least 60%, an involved-to-uninvolved serum free light-chain ratio of at least 100 with an involved free light-chain concentration of at least 100 mg/L, and more than one focal lesion on MRI of at least 5 mm each.

Risk Stratification Moves Beyond a Single Label

Contemporary studies suggest median survival exceeding 10 years in transplant-eligible patients, with 4-year survival above 90%. In patients older than 65, median survival is approximately 7–8 years, with 5-year survival exceeding 70%. The current IMWG definition identifies several cytogenetic patterns associated with high-risk disease, including del(17p) and/or TP53 mutation, biallelic del(1p), gain(1q) combined with del(1p), and high-risk IgH translocations such as t(4;14), t(14;16), or t(14;20) when accompanied by gain(1q) or del(1p). The Mayo mSMART framework adds clinically aggressive features such as plasma cell leukemia, extramedullary disease, and a high S-phase fraction, and recognizes "double-hit" disease when multiple high-risk features coexist.

Quadruplets at the Frontline

Frontline therapy for newly diagnosed myeloma now rests on transplant eligibility and disease risk, with anti-CD38 (搜索)搜索该靶点-based quadruplets increasingly used in both groups. In the PERSEUS trial, daratumumab查看药品详情 plus VRd (Dara-VRd) produced a higher overall response rate (97% vs. 94%) than VRd alone, but the more telling result was 4-year progression-free survival (PFS) of 84% versus 68%. Overall survival at this follow-up was similar between arms, around 90%.

The IMROZ trial showed the same pattern with isatuximab查看药品详情, where Isa-VRd improved 5-year PFS from 45% (VRd) to 63%, with 5-year overall survival of 72% versus 66%, though this difference was not statistically significant. The BENEFIT trial cautioned against assuming more drugs are always better: in older patients, Isa-VRd produced somewhat higher response depth than Isa-Rd, but estimated 2-year PFS was 85% versus 80%, not a statistically significant difference.

The Transplant Question and Maintenance

In IFM 2009, early autologous stem cell transplant (ASCT) improved median PFS from 36 to 50 months, yet at 8 years overall survival was 60% with delayed transplant and 62% with early transplant. The US DETERMINATION trial reached the same conclusion under prolonged lenalidomide查看药品详情 maintenance, with median PFS increasing from 46 to 68 months but 5-year overall survival virtually identical at 79% versus 81%. High-risk disease is different, where 3–4 cycles of Dara-VRd or Isa-VRd followed by ASCT and maintenance may be preferred.

For maintenance, lenalidomide查看药品详情 has the longest evidence base, with randomized-trial meta-analysis showing improvements in both PFS and overall survival. In the phase III ENDURANCE trial, indefinite lenalidomide maintenance did not improve overall survival over a fixed 2-year course in standard-risk patients who had not undergone upfront ASCT, and was associated with greater toxicity.

Immunotherapy Moves Earlier in Relapse

CAR-T and bispecific antibodies are now core options at first and second relapse. In KarMMa-3, idecabtagene vicleucel查看药品详情 produced a response rate of 71% compared with 42% for standard regimens, with median PFS increasing from 4.4 to 13.3 months. The phase III CARTITUDE-4 trial produced even deeper responses with ciltacabtagene autoleucel查看药品详情.

Bispecific antibodies are challenging standard relapse regimens. In MajesTEC-3, teclistamab查看药品详情 plus daratumumab查看药品详情 was compared with standard daratumumab-based regimens, achieving 3-year PFS of 83.4% versus 29.7% and overall survival of 83.3% versus 65.0%. For patients already exposed or refractory to daratumumab, MajesTEC-9 showed teclistamab monotherapy achieved an 84.5% response rate, with 18-month PFS and overall survival of 69.8% and 79.2%, respectively.

The MonumenTAL-3 trial validated a different target, with talquetamab查看药品详情 directing T cells against GPRC5D (搜索)搜索该靶点. Both talquetamab-containing experimental arms produced statistically significant PFS and overall survival improvements versus DPd. Talquetamab carries a distinct toxicity profile including dysgeusia, appetite loss, weight loss, nail abnormalities, and skin toxicity.

Belantamab Returns Through Combination Therapy

Belantamab mafodotin查看药品详情 illustrates how a drug's fate can change with its schedule and combination partner. In DREAMM-7, belantamab-bortezomib-dexamethasone achieved a median PFS of 37 months compared with 13 months for daratumumab查看药品详情-bortezomib-dexamethasone. In DREAMM-8, belantamab-pomalidomide-dexamethasone improved PFS compared with bortezomib-pomalidomide-dexamethasone, with estimated 1-year PFS of 71% versus 51%. The main limitation remains ocular toxicity, with keratopathy occurring in the majority of patients at conventional dosing.

Smoldering Myeloma: Rethinking Observation

Smoldering multiple myeloma (搜索)搜索该疾病 (SMM) is clinically heterogeneous, with an average risk of progression of approximately 10% per year during the first 5 years after diagnosis, falling to around 3% annually over the next 5 years and 1.5% per year thereafter. The phase III AQUILA trial provided the strongest evidence for early treatment: in patients with high-risk SMM, daratumumab查看药品详情 given for 3 years improved 5-year PFS from 40.8% with active monitoring to 63.1%, supporting its approval in this setting.

Vincent Rajkumar, Professor of Medicine at the Mayo Clinic查看公司主页, described the AQUILA trial as "the first approved therapy for high risk smoldering myeloma" that "changed paradigm," noting it took 10 years from trial concept to publication and over 20 years from his first trial in SMM. Reflecting on the ENDURANCE trial, he emphasized the value of investigator-initiated trials, stating that "while pharma trials find X treatment forever is better than nothing, we need IITs to determine how much of X is actually needed for the effect."

Supportive Care and Emerging Options

Bone protection remains fundamental, with zoledronic acid or pamidronate recommended, while denosumab is particularly useful in patients with significant renal dysfunction. Herpes zoster prophylaxis with acyclovir or valacyclovir is recommended for patients receiving proteasome inhibitors or anti-CD38 (搜索)搜索该靶点 therapy, along with routine intravenous immunoglobulin for patients on bispecific antibodies.

Several newer immune-directed approaches are in development, including etentamig (a BCMA (搜索)搜索该靶点-directed bispecific antibody), cevostamab (targeting FcRH5 (搜索)搜索该靶点 and CD3), and ramantamig (a trispecific antibody targeting BCMA, GPRC5D (搜索)搜索该靶点, and CD3). The CELMoDs iberdomide查看药品详情 and mezigdomide provide another route beyond current immunotherapies, with iberdomide now an approved therapy following its August 2026 accelerated approval.